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ABSTRACT
This study aimed to molecularly characterise colorectal pulmonary metastases 
(PM) and investigate whether their molecular profiles were concordant with those of 
the primary tumour. Clinical data and archival formalin fixed paraffin embedded tissue 
samples were retrospectively collected from patients who underwent ≥ 1 pulmonary 
metastasectomies for colorectal cancer between 1997–2012. Primary tumour and 
metastatic samples were analysed using a targeted capture sequencing panel of 46 
cancer-associated genes. The 5-year progression-free and overall survival rates for the 
81 patients in this study were 32% (95% CI 22–42%) and 77% (95% CI 66–85%) 
respectively. Fifty-four patients had samples available from ≥ 1 PM, and sequencing 
data were successfully obtained from 33 PM from 24 patients. The most frequently 
mutated genes were APC (71%), KRAS (58%) and TP53 (46%). Seventy-three percent 
of the 15 patients with matched primary and PM samples and 6 of the 7 patients 
(86%) with data from ≥ 2 PM had concordant molecular profiles. The concordance for 
KRAS and NRAS was 100%. At our institutions, patients with resectable colorectal PM 
had a favourable prognosis. RAS mutations were commonly detected in PM and the 
molecular profiles of colorectal PM were highly concordant with the primary tumour. 
INTRODUCTION
Pulmonary metastases (PM) occur in approximately 
10–20% of patients with colorectal cancer [1–4]. The 
majority of patients with PM are treated with palliative 
intent and have a poor prognosis, but pulmonary 
metastasectomy may be a curative option for carefully 
selected patients with limited sites of disease. However, 
up to 68% of patients develop recurrent disease following 
initial metastasectomy [5, 6] and although selected patients 
with operable metastases may benefit from multiple 
re-resections [7, 8], many patients will ultimately develop 
incurable disease. 
Precision medicine involves selecting treatment 
based on the molecular characteristics of an individual 
patient’s tumour. In metastatic/advanced colorectal 
cancer, a patient’s suitability for treatment with anti-EGFR 
monoclonal antibodies is determined by the presence 
of mutations in KRAS and/or NRAS [9]. However, 
discordance between the molecular profiles of the primary 
tumour and metastases can occur due to heterogeneity of 
the primary tumour, the progression of specific tumour 
subclones, the gain or loss of mutations during disease 
progression or technical issues (such as low DNA 
quality) leading to inaccurate results [10, 11]. Tumour 
heterogeneity may limit the efficacy of targeted therapies 
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and therefore it is essential to establish whether there 
are significant molecular differences between primary 
tumours and metastatic sites of disease. 
KRAS mutation status has been shown to be highly 
concordant between the primary colorectal tumour 
and hepatic metastases [10, 12]. It has therefore been 
suggested that RAS results from analysis of the primary 
tumour are sufficient for clinical decision making and that 
additional RAS testing of metastatic sites is unnecessary. 
However, there is a paucity of data available on PM as the 
majority of previous studies focus on hepatic metastases. 
It is currently unclear if results from studies on hepatic 
metastases can be applied to metastases occurring at 
other sites, and there is some evidence that extra-hepatic 
metastases are more likely to show discordant molecular 
results [10]. To investigate this we performed next 
generation sequencing (NGS) on colorectal pulmonary 
metastasis samples to look for alterations in 46 cancer-
associated genes and compared the molecular profiles of 
the PM with those of the primary tumour. 
RESULTS
Patient characteristics and clinical outcomes
Eighty-one patients underwent 121 pulmonary 
metastasectomies. The baseline characteristics of these 
patients are shown in Table 1. Nineteen patients (23%) 
presented with synchronous metastases at the time 
of diagnosis. The details of the metastasectomies are 
shown in Supplementary Table 1. Eighty-eight of the 
121 metastasectomies (73%) were for unilateral 
metastases, neoadjuvant chemotherapy was given prior to 
58 (48%) of metastasectomies and all targeted therapies 
were given in combination with systemic chemotherapy. 
Mediastinal dissection was not routinely performed.
The median follow-up was 87 months (interquartile 
range (IQR) 72–113 months) and at the time of last 
follow-up, 23 patients (28%) remained disease-free. The 
in-hospital and 30-day mortality after metastastectomy 
was 0%. The median progression-free survival (PFS) and 
overall survival (OS) were 24 months (95% CI 19–38) and 
91 months (95% CI 72–131) respectively, and the 5-year 
PFS and OS rates were 32% (95% CI 22–42%) and 77% 
(95% CI 66–85%). Twelve patients (15%) also had PM 
treated by radiofrequency ablation (RFA) (1-4 separate 
RFA procedures per patient), 38 patients (47%) received 
≥ 1 lines of palliative chemotherapy and 28 patients (35%) 
had ≥ 1 resections of non-PM (mainly liver metastases). 
The number of resections (2+ vs. 1, HR 4.12 95% 
CI 2.35–7.23; p < 0.001) and the size of the largest 
pulmonary metastasis (> 11 mm vs. ≤ 11 mm, HR 0.53, 
p = 0.02, 95% CI 0.31–0.92; p = 0.02) were the only two 
factors associated with PFS. No factors were associated 
with OS. 
Molecular characteristics of pulmonary 
metastases
Figure 1 shows the availability of primary tumour 
and metastasectomy samples and whether these samples 
were successfully sequenced. One or more pulmonary 
metastasectomy samples were available for 54 patients 
(67%). Sequencing data were available for 33 PM from 
24 patients (6 patients had results for 2 PM and 1 patient 
for 4 PM). Of these 24 patients, sequencing data were also 
available for the primary tumour for 15 patients and from 
another metastatic site in 2 patients. 
The most frequently altered genes in the first 
available PM sample for each patient were APC 
(n = 17, 71%), KRAS (n = 14, 58%) and TP53 (n = 11, 
46%) and further details of these alterations are shown in 
Supplementary Figures 1–3 and Supplementary Table 2 
(in some samples > 1 variant for each gene was detected). 
Mutations were also detected in PIK3CA (n = 5, 21%), 
FBXW7 (n = 4, 17%), CTNNB1 (n = 3, 13%) and TCF7L2 
(n = 3, 13%). Mutations in ATM, NRAS and PTEN were 
detected in 2 samples each and mutations in ARID1A, 
BRAF, CDKN2B, ERBB4, NOTCH3 and RET in 1 sample 
each. RAS mutations were detected in 15 of the 24 patients 
(63%) with sequencing results from PM samples (KRAS 
mutant/NRAS wild-type: 13 patients, NRAS mutant/
KRAS wild-type: 1 patient, KRAS mutant/NRAS mutant: 
1 patient). No amplifications or translocations were 
detected in the genes that were interrogated by our assay. 
Concordance between the molecular 
characteristics of the primary tumour and 
matched pulmonary metastases
Eleven (73%) of the 15 patients with matched 
primary and PM samples had concordant molecular 
profiles and of the 7 patients with more than one PM 
sample, 6 (86%) had concordant molecular profiles (see 
Table 2). An example of the results for an individual 
patient is shown in Supplementary Figure 4. The molecular 
profiles of the two non-pulmonary resection samples (one 
liver and one pancreatic metastasis) were concordant with 
the respective primary tumours. 
In patients with sequencing data from matched 
samples, the concordance between the primary tumour 
and the PM for KRAS, NRAS and BRAF was 93% (14/15), 
100% (15/15) and 100% (14/14 patients) respectively. 
BRAF results were not successfully obtained from a 
matched PM sample in 1 patient due to suboptimal 
coverage. The patient with discordant KRAS results 
(patient 002) had a KRAS mutation detected in their 
primary tumour and first PM, but this mutation was not 
detected in their second PM using NGS. The most likely 
reason for this is that the second PM was highly necrotic 
and had a very low tumour content. Digital droplet 
Oncotarget65001www.impactjournals.com/oncotarget
Table 1: Patient characteristics (n = 81)
Characteristic N (%)
Gender
  Male
  Female
50 (62)
31 (38)
Median age (interquartile range) at diagnosis, years 62 (54–67)
Site of primary tumour
  Caecum/ascending colon
  Transverse colon
  Sigmoid/rectosigmoid
  Rectum
  Colorectal (site not specified)
7 (9)
3 (4)
25 (31)
42 (52)
4 (5)
Stage at diagnosis
  I
  II
  III
  IV
  unknown
3 (4)
19 (24)
38 (47)
19 (24)
2 (3)
Differentiation
  Well
  Moderate
  Poor
  Unknown
1 (1)
64 (79)
5 (6)
11 (14)
Extramural venous invasion (EMVI)
  No
  Yes
  Unknown
27 (33)
18 (22)
36 (44)
Neoadjuvant treatment of primary tumour
  Neoadjuvant chemoradiotherapy
  Neoadjuvant chemotherapy
  Neoadjuvant chemotherapy and chemoradiotherapy
  Neoadjuvant radiotherapy 
13 (16)
6 (7)
12 (15)
2 (3)
Adjuvant treatment of primary tumour
  Adjuvant chemotherapy
  Adjuvant chemoradiotherapy
57 (70)
3 (4)
Site of first metastasis
  Lung only
  Liver only
  Lung and other site1
60 (74)
14 (17)
5 (6)
Median time from diagnosis to first metastasis at any site (IQR), months 16 (1–28)
Median time from diagnosis to first pulmonary metastasis (IQR), months 19 (2–29)
Number of pulmonary metastasectomies per patient2
  1
  2
  3
  4
  5
52 (64)
22 (27)
4 (5)
2 (3)
1 (1)
1Other sites: lymph node, peritoneum, liver.
2Staged metastasectomies were performed in 23 patients with bilateral metastases and were counted as one metastasectomy 
as no other treatment was administered between each surgical procedure. 
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Figure 1: Availability of primary tumour and metastasectomy samples.
Table 2: Concordance between the molecular characteristics of the primary tumour and matched 
lung metastases by NGS
Patient no. Stage at diagnosis
Genes containing alterations (mutations, insertions or deletions)
All samples 
concordantPrimary tumour 1st pulmonary metastasis 2nd pulmonary metastasis
3rd pulmonary 
metastasis
4th pulmonary 
metastasis
Other 
metastasis
002 T4 N0 M0 APC, KRAS, PIK3CA APC, KRAS, PIK3CA No variants detected - - - No1
005 T3 N0 M0 FBXW7 FBXW7 - - - FBXW7 Yes
007 T2 N1 M0 TP53, ARID1A TP53, ARID1A - - - - Yes
011 T3 N2 M0 APC, KRAS, TP53, 
FBXW7
APC, KRAS, TP53, FBXW7 - - - - Yes
019 T3 N0 M0 NRAS, PIK3CA, PTEN, 
SMAD4
NRAS, PIK3CA, PTEN, 
SMAD4
- - - - Yes
021 T2 N0 M0 No sample available APC, KRAS APC, KRAS - - - Yes
025 T3 N1 M0 APC, KRAS APC, KRAS - - - - Yes
032 T3 N1 M0 APC, KRAS, TP53, 
CTNNB1, NOTCH3
APC, KRAS, TP53, 
CTNNB1, NOTCH3
- - - - Yes
0332 T2 N0 M0 No sample available APC, KRAS, FBXW7 APC, KRAS, 
FBXW7
APC, KRAS, FBXW7 APC, KRAS, 
FBXW7
- Yes
037 T1 N1 M0 APC (2 mutations), 
KRAS, PIK3CA, TP53
APC (1 APC deletion not 
detected), KRAS, PIK3CA, 
TP53
- - - - No1
0382 T3 N2 M0 No sample available APC, BRAF, TP53, 
CDKN2B 
APC, BRAF, 
TP53,CDKN2B
- - - Yes
040 T3 N1 M0 APC, KRAS APC, KRAS - - - APC, KRAS Yes
041 T3 N1 M0 APC, TP53, ATM, 
CTNNB1
APC, TP53, ATM, CTNNB1 APC, TP53, ATM, 
CTNNB1
- - - Yes
045 T4 N0 M1 APC No variants detected - - - - No1
050 T3 N2 M0 APC, KRAS, TP53, 
TCF7L2
APC, KRAS, TP53, 
TCF7L2
- - - - Yes
051 T3 N0 M0 APC, KRAS, PIK3CA, 
TP53, AKT1, SMAD4, 
TCF7L2
APC, KRAS, TP53, 
TCF7L2 (AKT1, PIK3CA, 
SMAD4 mutations not 
detected)
- - - - No1
052 T2 N0 M1 KRAS, NRAS, PIK3CA, 
TP53, CTNNB1
KRAS, NRAS, PIK3CA, 
TP53, CTNNB1
- - - - Yes
056 T3 N1 M0 No variants detected No variants detected No variants detected - - - Yes
0632 T3 N2 M0 No sample available APC, TP53 APC, TP53 - - - Yes
1ddPCR for PIK3CA and KRAS on the 2nd pulmonary metastasis sample for patient 002 detected low frequency mutations in these genes. ddPCR was not performed for APC in patient 002 or the other 
discordant samples as probes were not available for the other variants. Discordant results are likely to be due to low tumour content of these samples. 2Patients 033, 038, and 063 had bilateral pulmonary 
metastases. 033: 1st pulmonary metastasis = left lung, 2nd pulmonary metastasis = right lung, 3rd pulmonary metastasis = left lung (2nd resection), 4th pulmonary metastasis = right lung (2nd resection). 
038 and 063: 1st pulmonary metastasis = left lung, 2nd pulmonary metastasis = right lung.
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polymerase chain reaction (ddPCR) of the primary tumour 
and second PM samples for this patient (see Figure 2) 
showed that KRAS and PIK3CA mutations occurred in the 
primary tumour at a higher fractional abundance than in 
the second PM (20.8 versus 0.29 for KRAS and 18.0 versus 
0.11 for PIK3CA respectively). This patient did not receive 
any systemic anti-cancer therapy between the first and 
second pulmonary metastasectomies. Three other patients 
had discordant results. Two of these patients (patients 
037 and 045) had an APC variant detected in the primary 
tumour but not in the PM sample whilst for the third patient 
(patient 051) PIK3CA, AKT1 and SMAD4 mutations were 
detected in the primary tumour but not in the PM sample. 
These discordant results are likely to have been due to 
the low tumour content of the corresponding pulmonary 
metastasectomy samples (< 10–20%), so any mutations 
present may have fallen below the level of detection using 
NGS. Between the date the primary tumour was resected 
and the date of pulmonary metastasectomy, patients 037 
and 045 received chemotherapy with capecitabine and 
oxaliplatin and patient 051 received chemotherapy with 
capecitabine (adjuvant treatment) and then 5-fluorouracil 
and irinotecan (neoadjuvant treatment). 
DISCUSSION
This study provides information on both the 
clinical and molecular characteristics of patients with 
colorectal PM. In our series, there was a high proportion 
of patients with rectal tumours and 63% of patients were 
RAS mutant. This is in keeping with previously published 
data that suggested an association between both rectal 
tumours and KRAS mutations and the development of PM 
[1, 13–15], although the KRAS mutation rates previously 
reported range from 36–62% for PM samples [13, 16–18]. 
Other studies have also shown that the presence of KRAS 
mutations is a poor prognostic factor both in colorectal 
cancer in general and specifically in patients with colorectal 
lung metastases [16, 18, 19], although this may be partly 
due to patients with RAS mutations being unsuitable for 
treatment with anti-EGFR monoclonal antibodies.
Our patients had a 5-year OS rate of 77%, which 
is higher than the 5-year OS rates of 40–68% reported 
by other series [7, 20]. Due to the retrospective nature of 
our study and the limited availability of samples there are 
multiple potential confounding factors that may account 
for the differences in patient outcomes, including careful 
patient selection, however it is noteworthy that many of 
our patients were aggressively treated, with many patients 
undergoing multiple resections (both for PM and for other 
sites of disease). 
Our study is one of only a few studies that have 
characterised the molecular profiles of colorectal PM 
and in general, the molecular profiles were consistent 
with those expected for primary colorectal cancer [21]. 
Currently, the most clinically significant mutated genes 
in colorectal cancer are KRAS, NRAS and BRAF as these 
genes provide information on a patients’ prognosis and 
their suitability for anti-EGFR therapies [9, 22].  Previous 
data have suggested that the status of these genes is highly 
Figure 2: Digital PCR detected mutations that were below the level of detection by NGS in patient 002.
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concordant between the primary tumour and metastases, 
with concordance rates of 92% for KRAS and 97% for 
BRAF [23]. The majority of these data are based on 
studies of hepatic metastases and extra-hepatic sites appear 
to have a lower concordance rate (95% concordance for 
hepatic metastases vs 86% for extra-hepatic metastases, 
p = 0.01) [10]. Similarly, Kim et al performed automated 
sequencing using capillary electrophoresis technology 
(ABI 3130xl Genetic Analyzer) and reported that PM have 
a high discordance rate for KRAS status (32.4%, 12/37, 
p = 0.014) [14]. In our patients, the concordance (by 
NGS and ddPCR) between the primary tumour and PM 
was 100% for KRAS, NRAS and BRAF. PM samples have 
a low tumour content and so our higher than expected 
concordance rates may be at least partly due to advances 
in sequencing methodology compared to previous studies.
 The discordant results we obtained in the primary 
versus PMs are likely to have been due to the technical 
constraints of our NGS panel and the low tumour content 
of the PM samples. For example, variants may have been 
present at a frequency of < 5% and were therefore below 
the ≥ 5% variant allele cut-off used to call mutations 
using the NGS panel. This hypothesis is supported by the 
results of the ddPCR experiments in patient 002. In this 
patient, the PM sample was highly necrotic and had a low 
tumour content. Our NGS panel did not therefore have the 
sensitivity to detect mutations in the PM sample, but ddPCR 
(which has a higher sensitivity) detected mutations in KRAS 
and PIK3CA that were below the level of detection by NGS. 
The majority of previous studies investigating the 
concordance of the mutational profile of metastatic sites 
with that of the primary tumour focused on a limited 
number of genes (e.g. KRAS). Studies that performed a 
more comprehensive molecular analysis have revealed 
a more complex picture. For example, Danner et al. 
performed comparative genomic hybridisation on 
colorectal tumours and matched PM and demonstrated 
that PM were more likely to have losses in 5q (26% 
vs 3%, p = 0.012) [24] where APC resides. Similarly, 
Vermaat et al. analysed 1,624 cancer-associated genes in 
matched primary tumours and hepatic metastases from 21 
patients using targeted deep-sequencing [25]. This study 
showed that the hepatic metastases gained an average of 
83 potentially function-impairing variations and lost an 
average of 70 variations, including abnormalities in genes 
encoding components of pathways such as the EGFR/
PI3K/VEGF pathway [25]. Our study is one of the most 
detailed analyses of colorectal PM performed to date 
(investigating mutations and copy number variations), and 
we have shown that PM have similar molecular profiles 
to those of the primary tumour. It is possible that this is 
because we analysed 46 genes that are known to develop a 
mutation early in tumorigenesis. A more unbiased analysis 
may detect greater differences between the primary 
tumour and the PM, but these may not necessarily be 
therapeutically meaningful.  
The results of our study are limited by the small 
number of patients for whom molecular results were 
available from both the primary tumour and a PM. It 
was not possible to locate a high proportion of samples 
due to the long inclusion period of 15 years and as 
no blood samples were available, the only source of 
germline DNA was normal tissue samples and these 
were frequently not available. In addition, due to the 
retrospective nature of this study, all DNA samples were 
formalin fixed paraffin embedded (FFPE) derived and 
some of the original primary tumour resections were 
almost 20 years old (although the date of resection did 
not appear to influence the sequencing success rate). 
The gene panel required a substantial amount of DNA 
(200–400 ng), and many samples did not yield sufficient 
DNA for analysis. There were a number of reasons for this, 
including exhaustion of samples by previous standard-
of-care analyses or use in other clinical trials, a previous 
unsuccessful attempt to perform exome sequencing on 
these samples (which failed as DNA extracted using Cobas 
resulted in poor quality libraries and led to all the samples 
being re-extracted using Qiagen) and tumour regression 
in resection samples due to neoadjuvant chemotherapy/
chemoradiotherapy. However, this study also provides 
important information on the feasibility of future genomic 
studies in similar patient cohorts. 
In summary, patients treated for resectable colorectal 
PM at our institutions had a favourable prognosis. After 
adjusting for tumour content, the molecular profiles of 
the PM were highly concordant with those of the primary 
tumour with respect to the 46 genes included in the NGS 
panel and so RAS results from the primary tumour may be 
sufficient for clinical decision-making regarding the use of 
anti-EGFR therapy. 
MATERIALS AND METHODS
Patients
After approval from a research ethics committee 
(REC reference 12/SC/0158), surgical records were used 
to identify patients who underwent one or more pulmonary 
metastasectomies for colorectal adenocarcinoma with 
curative intent between 1997 and 2012 at the Royal 
Brompton and Harefield NHS Foundation Trust. Only 
patients who had received treatment at the Royal Marsden 
and patients whose pulmonary nodules were found to be 
related to their colorectal adenocarcinoma were included. 
Clinical information, including patient demographics, 
clinical and pathological characteristics, treatment details 
and patient outcomes were retrospectively collected from 
electronic patient records. 
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Sequencing methods
Archival FFPE tissue samples surplus to clinical 
requirements were collected from patients’ colorectal 
primary tumours, pulmonary metastasectomy specimens 
and any other resected metastases (e.g. liver metastases). 
No blood samples were available hence representative 
areas of normal tissue (e.g. from resected colon or 
pulmonary specimens) were selected to provide germline 
DNA for comparison. 
5 × 10 μm unstained slides and two haematoxylin 
and eosin stained slides were cut from FFPE blocks. 
Tumour content and purity were assessed using the stained 
slides and the tumour areas were marked by experienced 
pathologists.  Unstained slides were macrodissected, if 
necessary, and DNA extracted using the QIAamp DNA 
FFPE Tissue kit (Qiagen).  DNA was assessed for quality 
using the Genomic DNA Analysis ScreenTape on the 
2200 TapeStation (Agilent).  Control sample DNA was 
extracted from FFPE tissue using the QIAamp DNA FFPE 
Tissue kit (Qiagen). DNA samples were quantified using 
Qubit High Sensitivity kit (Life Technologies). 200 ng 
of DNA with an average molecular weight > 1000 bp or 
400 ng of DNA with an average molecular weight < 1000 bp 
(both tumour and control) were used in the HyperPlus 
kit (KAPA Biosystems) to generate sequencing libraries. 
Libraries from 2–3 patients were combined with a positive 
control (Human Male genomic DNA (Promega)) and non-
template control and hybridisation capture was performed 
using SeqCap EZ Choice Enrichment kit (Nimblegen). 
The enrichment kit was designed against 46 genes and 
details of the gene panel are shown in Table 3. The genes in 
the panel were chosen because they were of prognostic or 
predictive significance, were targets in current/forthcoming 
clinical trials in gastrointestinal cancers or were known 
to be recurrently mutated in gastrointestinal cancers.  As 
all the samples were FFPE they were all combined in a 
single pool alongside a positive (Promega) and non-
template control. Samples were pooled according to trial 
identifier (typically 2–3 sample sets per pool) resulting 
in pools between 3–7 samples and controls (most pools 
contained 7 samples). The single pool containing all 
the samples was then hybridised. Combined libraries 
were sequenced on a MiSeq instrument (Illumina) with 
2 × 76 bp reads using MiSeq reagents v3 chemistry.  
The gene panel and its analytical procedures had 
been validated to the level required for routine clinical 
use in a Clinical Pathology Accredited laboratory. The 
validation process involved analysing 50 colorectal 
tumour tissue samples collected as part of a previous 
study (the Screening Study of Genetic Changes in 
Colorectal Cancer), which had established a database of 
tissue and blood samples from patients with colorectal 
cancer. These samples had previously been analysed 
for KRAS, BRAF, NRAS, PIK3CA and TP53 mutations 
using either Capillary Electrophoresis-Single Strand 
Conformational Analysis (CE-SSCA), a COBAS 
polymerase chain reaction (PCR) based mutation test or 
Tru-Seq Custom Amplicon next generation sequencing 
(TSCA NGS). Twenty-seven patients were known to 
have KRAS mutations, 13 had BRAF mutations, 12 had 
PIK3CA mutations and 2 had NRAS mutations. The 
results obtained from the gene panel were compared with 
the known mutational profile of these samples and the 
sensitivity and specificity was 100% for all genes with 
the exception of PIK3CA, which had a specificity of 
89.5%.  This lower specificity was due to the detection 
of 8 additional mutations that had not previously been 
detected and 4 mutations which were below the threshold 
frequency for detection by previous methods (mutation 
frequency ranged from 1.94–9.55%). Many of these 
mutations had not been previously reported or were very 
rare. The other genes in the panel were not validated as 
there were no gold-standard test results for these genes, 
and therefore validation of these genes was extrapolated 
from the validation of KRAS, BRAF, NRAS and PIK3CA. 
The gene panel had also been used to analyse samples 
from 136 patients with gastrointestinal malignancies who 
Table 3: Genes included in the targeted capture panel
Mutations
AKT APC ARID1A ATM BRAF CDK4 CDKN2A/B
CTNNB1 DOCK2 EGFR ELMO1 ERBB2/4 FBXW7 HRAS
IDH1/2 JAK3 KIT KRAS MAP2K1/2 NOTCH1/2/3 NRAS
PDGFRA PIK3CA PTEN RET ROS1 SMAD4 TCF7L2
TP53 UGT1A1 VHL
Copy number amplification
ALK CCND1 CDK4/6 EGFR ERBB2 FGFR2 IGF1/2
KRAS MET MST1R PIK3CA TRIM44
Translocations
ALK FGFR2 RET ROS1
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had been recruited into a molecular profiling feasibility 
study (ClinicalTrials.gov identifier NCT02112357).
Analysis
The primary analysis was performed through MiSeq 
Reporter (v2.5.1; Illumina) to generate binary alignment map 
(bam), coverage and variant files. The secondary analysis 
was performed through an in-house Molecular Diagnostics 
Information Management System to generate QC, variant 
annotation, data visualisation and a clinical report. In 
the Molecular Diagnostics Information Management 
System, the bam files were taken and de-duplicated using 
Picard to generate metrics for each region in the panel of 
interest. Oncotator (v1.5.3.0) was used to annotate point 
mutations and indels. Annotations include gene names, 
functional consequence (e.g. Missense), PolyPhen-2 
predictions, and cancer-specific annotations from resources 
such as COSMIC, Tumorscape, and published MutSig 
results. All potential mutations and copy number variations 
were visualised using Integrative Genomics Viewer and two 
scientists were required to analyse the results and review the 
mutation report blindly and independently.
Digital droplet polymerase chain reaction
ddPCR of FFPE tumour derived DNA from a patient 
with discordant molecular results was performed using the 
QX200 ddPCR system (BioRad). TaqMan assays were 
designed to match mutations of interest and validated on 
a positive sample prior to use. The assays were performed 
using ddPCR Supermix for Probes (BioRad), and droplets 
generated on QX200 Automated Droplet Generator 
(BioRad) according to the manufacturer’s instructions. 
5 ng of input FFPE tissue-derived DNA were analysed 
in each well. Each reaction was partitioned to a median 
of 16,000 droplets, including a tested sample (ran in 
duplicate), positive, negative controls and nontemplate 
control (nucleic acid-free water). Emulsified PCR 
reactions were run on a 96-well plate on a BioRad thermal 
cycler, incubating the plates at 95°C for 10 min, followed 
by 40 cycles at 95°C for 15 sec and 60ºC for 60 sec, then 
by a 10 min incubation at 98°C. The temperature ramp 
increment was 2.5°C/sec for all steps. Plates were read on 
a BioRad QX200 droplet reader using QuantaSoft version 
1.7.4.0917 software from BioRad. Number of droplets 
positive for mutant DNA, wild type DNA, both, or neither 
was assessed, and fractional abundance calculated for each 
well (or merged wells for tested sample).
Statistical considerations
The sample size was limited by the number of 
patients who had undergone pulmonary metastasectomies 
and who had sufficient DNA for analysis. The majority of 
the analysis is descriptive. The frequency of alterations 
in each gene was calculated and the mutational profile of 
the colorectal primary tumour was compared to the profile 
of the metastases in order to determine the concordance 
between the samples. 
The date of diagnosis of pulmonary metastatic 
disease was defined as the date PM were first detected 
by CT imaging. PFS was calculated from the date of 
diagnosis of pulmonary metastatic disease to the date of 
progression or death from any cause. OS was calculated 
from the date of diagnosis of pulmonary metastatic disease 
to the date of death from any cause. Patients without an 
event were censored at the time of last follow-up. Cox 
proportional hazards models were used to investigate 
whether the number of pulmonary metastasectomies 
(2+ vs. 1), pre-operative CEA (> 4 vs. ≤ 4), site of primary 
tumour (colon vs. rectum), size of largest metastasis 
(11 mm vs. ≤ 11 mm), number of metastases (> 1 vs. 1), site 
of PM (unilateral vs. bilateral), neoadjuvant chemotherapy 
(yes vs. no), adjuvant chemotherapy (yes vs. no), site of 
first metastasis (pulmonary only vs. other) and time to first 
metastasis were associated with PFS and OS. 
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